Drug intelligence / Profile preview

HCP1305

Development stage: Discontinued
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules

Overview

HCP1305 is a small molecule drug developed by Hanmi Pharmaceutical for the treatment of hypercholesterolemia and other cardiovascular and metabolic diseases. It reached phase 3 clinical trials in South Korea for indications including hyperlipidemias, hypertension, and hypercholesterolemia but was ultimately discontinued. The precise mechanism of action has not been disclosed publicly, though it was described as an antihypertensive agent. No further details on its molecular target or pharmacological class have been published[1][3][5][9].

Beyond the preview

Go deeper on HCP1305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCP1305.

Explore the full profile